Changes in Beneficial Ownership · 4
Dyne Therapeutics, Inc.
DYNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-08172026_050803.xml
Filing details
- Report period
- 2026-08-13
- Issuer
- Dyne Therapeutics, Inc.
- Issuer CIK
- 0001818794
- Trading symbol
- DYN
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Rhodes Jason P
- Reporting owner CIK
- 0001577014
- Relationship
- Director
- Address
- C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-13 | S · Form 4[F1] | 268,354 | D | 26.20[F2] | 3,801,128 | I | See footnote[F3] |
| Common Stock | 2026-08-13 | S · Form 4[F1] | 94,415 | D | 26.20[F2] | 1,045,735 | I | See footnote[F4] |
| Common Stock | 2026-08-13 | S · Form 4[F1] | 63,643 | D | 26.20[F2] | 751,411 | I | See footnote[F5] |
| Common Stock | 2026-08-14 | S · Form 4[F1] | 1,359,674 | D | 25[F6] | 2,441,454 | I | See footnote[F3] |
| Common Stock | 2026-08-14 | S · Form 4[F1] | 478,377 | D | 25[F6] | 567,358 | I | See footnote[F4] |
| Common Stock | 2026-08-14 | S · Form 4[F1] | 322,465 | D | 25[F6] | 428,946 | I | See footnote[F5] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 2,962 | I | See footnote[F7] |
Table key
- I
- Indirect
Footnotes
- F1
- Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
- F2
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6).↩ 1↩ 2↩ 3
- F3
- The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.↩ 1↩ 2
- F4
- The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.↩ 1↩ 2
- F5
- The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.↩ 1↩ 2
- F6
- The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive.↩ 1↩ 2↩ 3
- F7
- The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.↩ 1
Signature 1
- Signed
- /s/ Ommer Chohan, Attorney-in-Fact
- Date
- 2026-08-17
Company context
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.